2024
Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart review
2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2020
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.Peer-Reviewed Original ResearchConceptsReduced intensity conditioning regimenIntensity conditioning regimenExtracorporeal photopheresisConditioning regimenChronic extensive GVHDTotal body irradiationChronic graftECOG-ACRINExtensive GVHDGVHD prophylaxisHost diseaseMycophenolate mofetilCell infusionMulticenter trialTolerogenic stateAggressive lymphomaBody irradiationMedian timeMyelodysplastic syndromeGrade 3Day 100PatientsCellular therapyConsecutive daysAdequate engraftment
2012
Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis
Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis. Photodermatology Photoimmunology & Photomedicine 2012, 28: 250-257. PMID: 22971190, DOI: 10.1111/j.1600-0781.2012.00689.x.Peer-Reviewed Original ResearchConceptsDuration of responseOverall response rateExtracorporeal photopheresisOverall survivalSkin responseResponse rateImpact of ECPCutaneous T-cell lymphomaMedian overall survivalSurvival of patientsT-cell lymphomaLong-term treatmentECP initiationDurable responsesPivotal trialsPatientsCohortECP treatmentModern criteriaSurvivalTreatmentDiagnosisTrialsMonthsResponse
2010
Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy
Berger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, Edelson R. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 2010, 116: 4838-4847. PMID: 20720185, PMCID: PMC3321745, DOI: 10.1182/blood-2009-11-256040.Peer-Reviewed Original ResearchMeSH KeywordsAntigen PresentationCell DifferentiationCell SeparationDendritic CellsFlow CytometryGene ExpressionGraft vs Host DiseaseHumansImmunophenotypingIn Situ HybridizationLymphoma, T-Cell, CutaneousMonocytesOligonucleotide Array Sequence AnalysisPhotopheresisReverse Transcriptase Polymerase Chain ReactionConceptsCutaneous T-cell lymphomaCostimulatory surface moleculesHuman dendritic cellsT-cell lymphomaDC differentiation pathwayAutoreactive disordersTherapeutic DCsDifferentiation pathwayHost diseaseDendritic cellsExtracorporeal photochemotherapyDistinctive molecular signaturesClinical efficacyOrgan rejectionCancer immunotherapyFunctional DCsEndogenous antigensNormal monocytesNormal subjectsClinical successCell differentiation pathwayLevel of expressionDisease statesMonocytesEnhanced expression
2007
Cutaneous T-cell lymphoma: Biologic targets for therapy
Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports 2007, 2: 272-277. PMID: 20425380, DOI: 10.1007/s11899-007-0037-8.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsApoptosisCD4 AntigensClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsDrug DesignEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansImmunologic FactorsImmunotherapyInterferon-gammaInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsPhotopheresisRecombinant Fusion ProteinsSkin NeoplasmsT-Lymphocyte SubsetsTumor EscapeConceptsCutaneous T-cell lymphomaReceptor-dependent signaling pathwaysEpigenetic changesSignaling pathwaysClonal populationsSkin-homing lymphocytesT-cell lymphomaT cell activationPersistence of tumorHost immune systemCTCL cellsCancer immunosurveillanceImmune cellsLangerhans cellsCytotoxic phenotypeDisease pathogenesisBiologic targetsImmune systemCellsTherapyDiseasePhenotypePathwayImmunosurveillanceActivation
2005
Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors
Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation 2005, 35: 1187-1193. PMID: 15852025, DOI: 10.1038/sj.bmt.1704984.Peer-Reviewed Original ResearchConceptsExtracorporeal photophoresisChronic graftHost diseaseSteroid-refractory chronic graftExtensive chronic graftHigh-risk patientsDe novo onsetUnfavorable risk groupCutaneous GVHDImmunosuppressive medicationsStable diseaseSteroid sparingOral ulcerationExtracorporeal photopheresisMedian durationNovo onsetProspective trialPrognostic factorsPrognostic scoreMedian timeProspective studyRisk groupsPatientsResponse rateProgressive onset
2003
Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease
Chan GW, Foss FM, Klein AK, Sprague K, Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 753-759. PMID: 14677114, DOI: 10.1016/j.bbmt.2003.08.002.Peer-Reviewed Original ResearchConceptsAcute GVHDHost diseasePreparative regimenExcess blastsAllogeneic transplantationDisease relapseGrade IIAllogeneic stem cell infusionReduced-intensity allogeneic transplantationReduced-intensity preparative regimenAllogeneic bone marrow transplantationHigh-risk MDS patientsExtensive chronic GVHDReduced-intensity transplantationTransplant-related mortalityFull donor chimerismTreatment-related mortalityStem cell infusionBone marrow transplantationMyelodysplastic syndrome patientsChronic myelomonocytic leukemiaSuccessful donor engraftmentChronic GVHDGVHD prophylaxisLess graftExtracorporeal Photopheresis in the Treatment of Graft-vs-Host Disease
Foss FM. Extracorporeal Photopheresis in the Treatment of Graft-vs-Host Disease. Journal Of Cutaneous Medicine And Surgery 2003, 7: 13-17. DOI: 10.1177/12034754030070s404.Peer-Reviewed Original ResearchAdrenal Cortex HormonesAdultAnimalsBone Marrow TransplantationChildClinical Trials as TopicDendritic CellsDisease Models, AnimalDogsFollow-Up StudiesGraft vs Host DiseaseHumansImmunosuppressive AgentsMicePentostatinPhotopheresisPilot ProjectsQuality of LifeRisk FactorsStem Cell TransplantationTime FactorsTissue DonorsTreatment OutcomeWhole-Body Irradiation
2002
Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease
Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100: 941-947. PMID: 12130506, DOI: 10.1182/blood-2002-01-0068.Peer-Reviewed Original ResearchConceptsMixed lymphocyte reactionAntigen-presenting dendritic cellsDendritic cellsT cellsChronic graftHost diseaseClinical responseDC populationsActivity of DCsAllogeneic bone marrow transplantationCD4/CD8 ratioMonocytic dendritic cellsAllogeneic T cellsEffector T cellsNatural killer cellsBone marrow transplantationTh2 cytokine profileChronic GVHDCD8 ratioCytokine profileECP therapyImmunologic mechanismsLymphocyte subpopulationsEffector lymphocytesKiller cells